View : 421 Download: 0
Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study
- Title
- Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: a nationwide cohort study
- Authors
- Kim, Min Ho; Oh, Hyung Jung; Kwon, Soon Hyo; Jeon, Jin Seok; Noh, Hyunjin; Han, Dong Cheol; Kim, Hyoungnae; Ryu, Dong-Ryeol
- Ewha Authors
- 류동열
- SCOPUS Author ID
- 류동열
- Issue Date
- 2021
- Journal Title
- KIDNEY RESEARCH AND CLINICAL PRACTICE
- ISSN
- 2211-9132
2211-9140
- Citation
- KIDNEY RESEARCH AND CLINICAL PRACTICE vol. 40, no. 4, pp. 660 - 672
- Keywords
- Chronic kidney disease; Mortality; Metformin; Renal insufficiency
- Publisher
- KOREAN SOC NEPHROLOGY
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Background: Metformin has recently been shown not to increase the risk of lactic acidosis in patients with chronic kidney disease (CKD). Thus, the criteria for metformin use in this population has expanded. However, the relationship between metformin use and clinical outcomes in CKD remains controversial. Methods: This study considered data from 97,713 diabetes patients with an estimated glomerular filtration rate of <60 mL/min/1.73 m2. The primary outcome was major adverse cardiac and cerebrovascular events (MACCE), and the secondary outcomes were allcause mortality and incident end-stage renal disease (ESRD). Results: Metformin users had a significantly higher risk of MACCE than non-users (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.14-1.26; p < 0.001). However, metformin users had a lower risk of all-cause mortality (HR, 0.78; 95% CI, 0.74-0.81; p < 0.001) and ESRD (HR, 0.44; 95% CI, 0.42-0.47; p < 0.001) during follow-up than non-users did. The relationships between metformin use and clinical outcomes remained consistent in propensity score matching analyses and subgroup analyses of patients with adequate adherence to anti-diabetes medication. Conclusion: Treatment with metformin was associated with an increased risk of MACCE in patients with diabetes and CKD. However, metformin users had a lower risk of all-cause mortality and ESRD during follow-up than non-users did. Therefore, metformin needs to be carefully used in patients with CKD.
- DOI
- 10.23876/j.krcp.20.222
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML